The inefficient treatment using
protein-based
nanovaccines is largely attributed to their inadequate immunogenicity. Herein, we developed a novel
fluoropolymer (PF) via ring-opening polymerization and constructed a
fluoropolymer-based
nanovaccine for
tumor immunotherapy. Due to the existence of fluoroalkyl chains, PF not only played a crucial role in
tumor antigen delivery but also exhibited a remarkable adjuvant effect in enhancing the immunogenicity of
nanovaccines. The
nanovaccines formed by mixing PF with a model
antigen ovalbumin (OVA) enhanced the uptake of
antigen proteins by dendritic cells (DCs) and promoted the maturation and antigen presentation of DCs. Compared with free OVA, PF/OVA showed better efficacy in both pre-
cancer prevention and
tumor treatment. Furthermore, the proportion of CD4+ T and CD8+ T cells was significantly increased in lymph nodes and
tumors of mice immunized with PF/OVA. Additionally, there was a great enhancement in the levels of key anti-
tumor cytokines (TNF-α and IFN-γ) in the serum of the PF/OVA immunized mice. Our research has shown that
fluoropolymer PF applied as a
protein vector and adjuvant has great potential for the development of
nanovaccines with robust immunogenicity.